Actuate Therapeutics, Inc.
ACTUActuate Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for high-impact, difficult-to-treat cancers.
Earnings
Next report
Nov 12, 2026 (In 1 week)Competitors
By market cap
Profile
Actuate Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for high-impact, difficult-to-treat cancers. The company's lead candidate, elraglusib, is a class-leading GSK-3β inhibitor designed to disrupt biological signaling cascades that promote tumor cell survival and growth. By targeting this master regulator, the company aims to provide a multimodal approach to treating a wide range of solid tumors and hematologic malignancies.
A clinical-stage pioneer in GSK-3β inhibition with Orphan Drug and Fast Track designations for its lead asset in pancreatic cancer.
FAQ
- What is Actuate Therapeutics, Inc.'s market cap?
- Actuate Therapeutics, Inc. (ACTU) has a market capitalization of $8.9M and trades on XNAS.
- Who are Actuate Therapeutics, Inc.'s competitors?
- Actuate Therapeutics, Inc.'s key competitors include Arcus Biosciences, Inc., Immuneering Corporation, Revolution Medicines, Inc., and others. These companies compete in similar markets and product categories.
- Who does Actuate Therapeutics, Inc. partner with?
- Actuate Therapeutics, Inc.'s notable partners include Northwestern University, University of Illinois-Chicago, Lantern Pharma Inc., and others.
- Where is Actuate Therapeutics, Inc. headquartered?
- Actuate Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.